ABSTRACT
The clinical spectrum of non-scaffold thrombosis (ST) elevation acute coronary syndromes (ACSs) is broad and ranges from patients free of symptoms at presentation, to patients with crescendo angina, to those presenting with ongoing ischemia, electrical or hemodynamic instability. The introduction of bioresorbable scaffolds paves the way for a new paradigm in the therapy of ACS. The transient nature of the scaffold struts offers a number of theoretical advantages compared to metallic drug eluting stent (DES), including a lesser induction of inflammatory reactions, potentially resulting in a less prolonged endothelial dysfunction after stenting. The clinical outcomes of bioresorbable vascular scaffold (BVS) implantation in the setting of acute coronary syndromes remain poorly explored. These can be classified into two major sections: anatomical and functional stabilization and clinical evidence. Clinical experience of BVS implantation in non-STEMI ACSs remains limited, but insights from large registries and preliminary data from one randomized trial suggest that it is associated with good acute and midterm performance.
